Chapter 15: Growth Hormone Secretagogues — CJC-1295, Ipamorelin, Tesamorelin, MK-677

"A correlate does not a surrogate make." — Thomas R. Fleming and David L. DeMets, Annals of Internal Medicine (1996)

Overview

Chapter 14 ended somewhere uncomfortable. Growth hormone itself is a real drug with a real approval and a genuinely narrow one: give it to a person whose pituitary does not make enough, and you correct a deficiency. Give it to a healthy adult in the hope of turning back time, and the human trials that have been done do not support the claim, while the side effect list is not hypothetical.

So the field did something clever. If injecting the hormone is the problem, don't inject the hormone. Ask the gland to make its own.

That is the entire idea behind growth hormone secretagogues, and it is the reason this class is the busiest corner of the consumer peptide market. The compounds in this chapter — CJC-1295, ipamorelin, sermorelin, GHRP-2, GHRP-6, MK-677, and tesamorelin — are not growth hormone. They are molecules that talk to your pituitary and ask it to release more of yours. The pitch that follows almost writes itself: it's your own hormone, your own pulses, your own feedback loops still intact, nothing suppressed, nothing foreign.

Here is the honest complication, and it is why this chapter is worth your time even if you have already made up your mind. That pitch contains real physiology. The mechanism works — these compounds genuinely raise growth hormone, and one of them holds a regulatory approval proving the strategy can produce a measured clinical result in a defined population.

Which is exactly what makes the class so easy to oversell. When a mechanism is real and demonstrable, and the blood test moves in the direction you were promised, it takes unusual discipline to keep asking the only question that matters: did anything happen to the person?

That question is the spine of this chapter. Section 15.7 — what "raises GH" proves and does not prove — is the most transferable thing in this book. Learn it here and you will use it on compounds that have not been invented yet.

Many readers of this chapter already use these compounds. This is not a lecture about that. It is the evidence, the unknowns, the genuine safety questions, and what a clinician can see that a vial and a forum cannot.

In this chapter, you will learn to:

• Describe the GH axis as a system with an accelerator, a brake, and a downstream messenger — and say which one a blood test can actually read
• Tell a GHRH analog from a ghrelin receptor agonist by receptor rather than by reputation
• Explain what "selective" means for ipamorelin and what it does not promise
• Say why MK-677 sits in a peptide chapter despite not being a peptide, and name its metabolic signal
• Use tesamorelin as the class's proof of concept and as the class's ceiling
• Give the strongest case for stimulating a gland rather than replacing its product — then dismantle it in three moves
• Separate a surrogate that reliably moves from an outcome that has not been shown to follow
• Rate four claims in this class and defend each rating with a falsifiable condition

Learning Paths

This is a full-read chapter for three of the five paths. It is also the chapter where the book's central discipline gets its hardest workout.

💊 GLP-1 — §15.7 is the section to read even if you skip the rest. The surrogate-versus-outcome problem you will meet here is the same one behind "but my A1c went down," and Chapter 12 assumes you have seen it once. 🏋️ Performance — read every word. This is your chapter. §15.6 and §15.8 are where the arguments you have actually encountered get taken seriously and then tested. 🔬 Science — §15.2 through §15.6 are the mechanistic core; §15.6 is a direct continuation of Chapter 3 §3.5 and pays off the GnRH precedent you were promised there. 💄 Cosmetic — skim §15.1 and read §15.7. The reasoning generalizes to every "it stimulates your own collagen" claim in Chapter 30. 🏥 Clinical — §15.4 (the glucose signal), §15.5 (the one approval), and §15.9 are the sections patients will bring to you, usually in that order and usually with the middle one missing.

15.1 The indirect strategy, and why it is genuinely appealing

Start with the question people actually arrive with.

If growth hormone is risky and hard to get and requires a prescription for a condition I don't have, why not just get my own body to make more of it?

That is not a naive question. It is close to a good one — physicians and pharmacologists asked a version of it deliberately, funded it, and built molecules to answer it, which is why several compounds in this chapter came out of real pharmaceutical programs rather than out of forums.

The reasoning goes like this. Chapter 14 showed that exogenous growth hormone has two problems separate from whether it works. First, when you supply a hormone from outside, the system that normally makes it notices and quiets down; the axis stays suppressed for as long as the supply continues. Second, an injection delivers a flat, sustained concentration that no healthy physiology ever produces, and Chapter 3 argued that this difference between a pulse and a plateau is frequently the whole difference between a hormone and a drug.

An indirect strategy appears to dodge both. Stimulate the gland instead of replacing its product and the gland stays in the loop, releasing in its own rhythm, under its own regulation. You are not overriding the system. You are, in the marketing phrase, "supporting" it.

Be careful here, because there is a real argument and a marketing slogan wrapped around it, and they are not the same object. §15.6 takes the real argument apart properly. For now, note what the strategy requires in order to work at all:

1. The pituitary must still be capable of making growth hormone. A secretagogue is an instruction, not an ingredient. If the gland is absent or damaged, no amount of signal produces hormone — which is why secretagogues are not a treatment for most severe growth hormone deficiency.
2. The stimulus must reach the pituitary in a form the receptor recognizes. Two different receptors are available, and the compounds in this chapter split cleanly between them.
3. The resulting hormone must produce something you care about. This is the step everyone skips.

Hold on to that third requirement. It is the only one that turns out to be hard.

Two doors into the same gland

The pituitary has two separate receptor systems that increase growth hormone release, and every compound in this chapter goes through one of them.

THE GH AXIS — accelerator, brake, and messenger

   HYPOTHALAMUS
        │  GHRH  ─────── accelerator          somatostatin ─────── brake
        │  (+)                                     (−)
        ▼                                           │
   ┌────────────────────── ANTERIOR PITUITARY ──────┴────────┐
   │                                                          │
   │   DOOR 1: GHRH receptor        DOOR 2: ghrelin receptor  │
   │   ← sermorelin                 ← GHRP-2, GHRP-6          │
   │   ← CJC-1295 (± DAC)           ← ipamorelin              │
   │   ← tesamorelin                ← MK-677 (not a peptide)  │
   │                                                          │
   └───────────────────────────┬──────────────────────────────┘
                               │  GROWTH HORMONE — released in PULSES,
                               │  mostly at night, near-undetectable between bursts
                               ▼
                            LIVER
                               │  IGF-1 — steady, measurable, the usable readout
                               ▼
                    muscle, bone, fat, everything else
                               │
                               └──── (−) feedback: IGF-1 inhibits GH release
                                          and raises somatostatin

Read that diagram twice, because three of its features do almost all the work in this chapter.

There is a brake as well as an accelerator. Hypothalamic GHRH stimulates pituitary GH release; somatostatin inhibits it. Growth hormone output at any moment is the net of the two. A compound that presses the accelerator does not disengage the brake, and — as we will see in §15.6 — pressing the accelerator harder is one of the things that makes the brake press back.

Growth hormone secretion is strongly pulsatile. It comes in bursts, mostly nocturnal, and between bursts circulating levels fall to nearly undetectable. This has a consequence that matters enormously for how anyone evaluates these compounds: a single random growth hormone measurement is nearly uninterpretable. A low value may mean a suppressed axis or may mean you drew blood between pulses. A high value may mean a stimulated axis or may mean you drew blood during one.

IGF-1 is the stable downstream measure. Growth hormone acts largely through insulin-like growth factor 1, produced mostly by the liver in response to GH. IGF-1 does not pulse the way GH does; it integrates GH exposure over a longer window, which makes it the number clinicians and trials actually use. When you read that a secretagogue "raised growth hormone," the underlying data is very often an IGF-1 measurement, and that is the appropriate choice.

And IGF-1 is also the feedback signal. The same molecule that lets you measure success is the one that tells the hypothalamus and pituitary to stop. Chapter 3 §3.4 established this pattern in general; here it has a specific consequence we will return to repeatedly. Any successful elevation of growth hormone raises IGF-1, and elevated IGF-1 inhibits GH release and raises somatostatin. The axis pushes back.

🔍 Check Your Understanding

1. A person reports that a random daytime blood draw showed "low growth hormone." Give two completely different explanations that are equally consistent with that result.
2. Why is IGF-1 the measurement of choice in trials of these compounds, and what makes that choice slightly awkward given what IGF-1 does in the axis?
3. A secretagogue is described as useful for "any case of low growth hormone." Name the situation in which it cannot possibly work, and say why.

15.2 GHRH analogs: sermorelin, CJC-1295, and the DAC question

The first door is the GHRH receptor on the pituitary — the same receptor your own hypothalamic GHRH uses. Compounds that act here are GHRH analogs, and their family resemblance is visible in the name: Chapter 1 §1.8 taught you that the stem -relin marks a releasing-hormone analog. Sermorelin, tesamorelin, and the GHRH portion of CJC-1295 are all built on the same idea.

Native human GHRH is 44 amino acids long, and — usefully — the biological activity lives in the first 29. That fragment, GHRH(1-29), is enough to activate the receptor, and essentially every GHRH analog you will encounter is a modified version of it.

Sermorelin is GHRH(1-29) itself, unmodified — and its history is worth knowing precisely because it is not the history of most compounds in Part III. Sermorelin received a generic name from an international naming authority, was developed formally, and was marketed — principally as a diagnostic agent for probing pituitary reserve and in pediatric growth hormone deficiency — before being withdrawn from the US market. Withdrawal for commercial reasons is a different fact from failure in trials, and honest reasoning keeps them apart. But note what this history is not: it is not evidence that sermorelin improves body composition, recovery, sleep, or aging in healthy adults, which is what it is now sold for. A compound can have a real regulatory past and no evidence whatsoever for its current popular claim.

Sermorelin's practical limitation is duration. Native GHRH is cleared quickly — its half-life is measured in minutes, because DPP-4 and other peptidases attack it promptly. This is exactly the problem Chapter 4 cataloged solutions to, and it is the problem CJC-1295 was built to solve.

🧬 The Molecule — what "CJC-1295" actually names, and why the answer is two molecules

CJC-1295 began as a real pharmaceutical program. The design idea was elegant and is worth understanding on its own terms, because you will meet the same trick in the GLP-1 chapters.

Start with GHRH(1-29). Add a small number of amino acid substitutions that block the sites where peptidases cut. You now have a modified GHRH fragment that survives longer than native GHRH — commonly written as modified GRF(1-29). Then, for the full version, attach a chemical group — the Drug Affinity Complex, or DAC — designed to form a covalent bond with albumin, the most abundant protein in blood plasma. Albumin circulates for weeks. A peptide tethered to it is effectively hidden from kidney filtration and from many proteases, and its duration of action goes from minutes to days.

That is CJC-1295 with DAC. Published early-phase human work in healthy adults reported what the design predicted: a single administration produced elevations in growth hormone and IGF-1 that persisted for days rather than hours. As a demonstration of protein engineering, it worked.

Here is the confusion you need to navigate. In the consumer market, the name "CJC-1295" is routinely applied to both the DAC version and the modified GRF(1-29) fragment without DAC — which are pharmacologically different molecules with duration profiles differing by more than an order of magnitude. Sellers often distinguish them as "CJC-1295 DAC" and "CJC-1295 no-DAC," but the labeling is inconsistent and the shorter-acting fragment is also sold under other names. Two compounds, one name, wildly different pharmacokinetics.

Sit with what that means for evidence. If you cannot tell which molecule a report refers to, you cannot aggregate reports. Every anecdote about "CJC-1295" is an anecdote about one of two different drugs, usually without saying which — which is why the informal evidence base for this compound cannot be repaired by collecting more of it.

And note the naming point from Chapter 1 §1.8. CJC-1295 is a laboratory code, and decades after the compound's description no generic name has been assigned, which tells you formal drug development did not run to completion. That is strong evidence about regulatory history and no evidence at all about pharmacology. The molecule may do exactly what its designers intended. The absence of a generic name speaks only to whether anyone finished testing it in humans against outcomes.

The DAC design raises a question that will not go away for the rest of the chapter, so let us name it now rather than later.

A compound engineered for extended duration delivers a sustained signal. The axis it is signaling is built to operate in pulses. Those are not the same thing done for longer. They are different inputs. §15.6 is where we take that apart, and it is the single most important structural argument in this chapter.

15.3 Ghrelin mimetics: GHRP-2, GHRP-6, ipamorelin, and what "selective" buys you

The second door is the growth hormone secretagogue receptor, usually written GHS-R, and better known as the ghrelin receptor.

Ghrelin is the stomach-derived hormone most people know as the hunger signal. It also potently stimulates growth hormone release. The receptor was characterized before its natural ligand was found, which is why it carries the clunky "growth hormone secretagogue receptor" name at all: pharmacologists found the door before they found the key.

Compounds acting here are called growth hormone releasing peptides (GHRPs) or, more accurately, ghrelin receptor agonists. Three matter for this chapter.

GHRP-6 is a hexapeptide and the historical prototype. It reliably stimulates growth hormone release, and it does something else reliably too: it stimulates appetite, which follows directly from what its receptor normally does. It is also associated with effects on cortisol and prolactin — the ghrelin receptor system does not sit in a sealed compartment, and stimulating it vigorously can nudge other pituitary outputs.

GHRP-2 is also a hexapeptide and generally described as more potent than GHRP-6 for GH release with somewhat less appetite stimulation. It is worth noting that GHRP-2 has been assigned the generic name pralmorelin, and where it appears in any formal medical use it has been as a diagnostic agent for assessing pituitary growth hormone reserve rather than as a treatment for anything. That distinction is easy to blur and important to hold: a compound approved somewhere to test an axis has not been shown to benefit anyone by stimulating it. A stress test is not a therapy.

Ipamorelin is a pentapeptide developed within a pharmaceutical program, and its design goal was selectivity. The intention was a compound that activates the ghrelin receptor to release growth hormone while producing substantially less of the appetite, cortisol, and prolactin activity that accompanies GHRP-6. In the descriptions available, it largely achieved that: ipamorelin is consistently characterized as the cleaner member of the family, and that reputation appears to be earned at the level of what it does to those measurements.

This is the point where a great many readers — reasonably — conclude that ipamorelin is therefore the "safe one." Let us be precise about what selectivity actually delivers.

⚠️ Hype Check — "ipamorelin is selective, so it's safe"

The claim, in its usual form:

"Ipamorelin is the selective one. It only stimulates GH — no hunger, no cortisol, no prolactin. That's why it's the safest secretagogue and why it's the one serious people use."

What's true in it, and it is a lot. Selectivity is a real pharmacological property and a real design achievement. Ipamorelin was deliberately engineered to separate GH release from the other effects of ghrelin receptor activation, and the characterizations available do support that it is cleaner than GHRP-6 on exactly those measures. Someone who says "ipamorelin causes less appetite stimulation than GHRP-6" is making a defensible statement.

Where it fails. Selectivity is a statement about which receptors a molecule engages. Safety is a statement about what happens to people who take it over time. These are different claims requiring different evidence, and the second does not follow from the first.

Three specific gaps.

First, selectivity says nothing about the consequences of the on-target effect. If chronically elevated growth hormone and IGF-1 carry risks — and Chapter 14's discussion of acromegaly established that sustained GH excess is not a benign state — then a compound that raises GH more cleanly delivers those on-target consequences more cleanly too. Precision in hitting a target is not protection from the target.

Second, "fewer measured off-target effects" is not "no off-target effects." The measurements that were made came back reassuring. The set of things measured in early characterization work is much smaller than the set of things that can happen to a person over years.

Third, there is no long-term human safety dataset to appeal to. Ipamorelin's development did not produce an approved product, so the multi-year safety follow-up that would exist for an approved drug does not exist here. Absence of reported harm from a compound never studied at scale is not evidence of absence of harm — it is absence of study, the failure mode Chapter 5 §5.2 named.

Verdict: the selectivity claim is largely accurate and the safety conclusion drawn from it is not supported. "Cleanest available option in a class with no long-term human outcome data" is a real statement and a much smaller one than "safe."

There is a further reason ipamorelin and CJC-1295 are so often discussed as a pair, and it deserves a straight explanation rather than a dismissal. The two act at different receptors, and the combination is described as producing a larger GH release than either alone. That is a coherent pharmacological expectation — pressing two independent accelerator pedals is not the same as pressing one harder, and synergy between GHRH-receptor and ghrelin-receptor stimulation is a real, described phenomenon in the endocrine literature. Note carefully what it establishes: a larger surrogate response, and nothing whatever about outcomes. §15.8 is where that gap gets measured.

15.4 MK-677: the one that isn't a peptide

MK-677, also called ibutamoren, is not a peptide. State that plainly, because the entire consumer market files it under "peptides" and it does not belong there chemically.

MK-677 is a small, orally active, non-peptide molecule that acts as a ghrelin receptor agonist — the same door as ipamorelin and the GHRPs, a completely different kind of molecule walking through it. It came out of a pharmaceutical discovery program aimed explicitly at that goal: find something that does what the GHRPs do, but that survives the stomach and can be swallowed.

They found one, and Chapter 1 §1.3 explains why that is a genuine achievement. A peptide swallowed on an empty stomach is food; MK-677 is not made of peptide bonds, so digestive proteases have nothing to cut. It is also long-acting.

So MK-677 sits in a peptide chapter for the same reason a hammer would sit in a chapter about screwdrivers: it is used for the same job, marketed alongside them, and mistaken for one constantly. Being precise about it is not pedantry — it changes what you should expect. Being orally active makes it easier to obtain and easier to take continuously, and "easier to take continuously" is a pharmacological fact whose consequences run straight into §15.6.

What MK-677 does to the surrogate is not in serious dispute. It raises growth hormone and IGF-1 reliably in humans, and it does so in a way that has been measured in real randomized trials in real people. That is more than can be said for most compounds in Part III, and it should be said clearly.

🔬 Read the Study

```text FIGURE 15.1 — "Two years of an oral secretagogue in healthy older adults" [Tier 2 — attributed, specifics unverified]

THE STUDY A randomized, double-blind, placebo-controlled trial of oral MK-677 in healthy older adults, run over approximately two years and reported in a major internal medicine journal in the late 2000s. Participants were community-dwelling older men and women, not patients with a diagnosed deficiency. Endpoints included IGF-1, body composition by imaging, and measures of strength and function.

THE QUESTION If you restore an older adult's GH and IGF-1 toward the levels typical of a healthy young adult, and you sustain that for two years, do the things people actually want — strength, function, capability — follow?

WHAT IT SHOWS The surrogate moved, decisively and durably. GH and IGF-1 rose into the range reported for healthy young adults and stayed there for the duration. Fat-free mass increased relative to placebo by an amount on the order of a kilogram to a kilogram and a half. Fasting blood glucose rose modestly, and measures of insulin sensitivity worsened.

WHAT IT DOESN'T It does not show a benefit in strength or physical function. The trial was not able to demonstrate that the added fat-free mass translated into people being stronger, faster, more capable, or more independent. It also cannot tell you what happens beyond two years, in younger adults, in people with different metabolic baselines, or at exposures other than those studied. And it cannot separate how much of the fat-free mass gain was contractile muscle from how much was fluid — GH axis stimulation causes sodium and water retention, which registers on a body composition scan as lean mass.

THE VERDICT A well-conducted trial that did the honorable thing: it measured the outcome and reported that the outcome did not follow the surrogate. This is the study that a fair-minded advocate of MK-677 and a fair-minded skeptic should both be able to cite, because it supports a real body composition effect and refuses to support the functional claim built on top of it.

THE LESSON "It restored my hormone levels to those of a 25-year-old" is a description of a blood test. Two years of exactly that, measured properly, did not produce two years of being stronger. Hold that sentence. It is §15.7 in miniature. ```

That trial is also where the class's most concrete safety signal lives.

🩺 Safety and Risk — the glucose signal, and why it is not a footnote

MK-677 has a documented signal for increased blood glucose and reduced insulin sensitivity. This is not an inference from mechanism or a theoretical worry raised by critics. It was measured, in randomized human trials, and it is described in the published record of the compound.

It is also exactly what the physiology predicts, which makes it more credible rather than less. Growth hormone is a counter-regulatory hormone: among its normal jobs is opposing insulin's action so that blood glucose is maintained during fasting. Chapter 14 noted that disordered glucose metabolism and frank diabetes are recognized features of sustained GH excess. Raise GH and IGF-1 durably and a shift toward insulin resistance is the expected direction of travel.

Why this matters more than it sounds like it does. The population most drawn to a compound promising better body composition overlaps substantially with the population already carrying metabolic risk. A modest, sustained worsening of insulin sensitivity is not dramatic on any single day and is not something a person feels. It shows up on a laboratory panel and nowhere else — which makes it exactly the kind of change a clinician can catch and a self-directed user cannot.

Two other recognized effects, both consistent with the mechanism. Fluid retention — GH axis stimulation causes sodium and water retention, which can produce swelling, joint discomfort, and carpal-tunnel-type symptoms, and which inflates lean mass measurements. Appetite stimulation — MK-677 acts at the ghrelin receptor, and increased hunger is commonly described. Whether that is a benefit or a problem depends entirely on why someone is taking it, which is a clean illustration of the principle that an effect is not a verdict.

None of this makes MK-677 uniquely dangerous. It makes it a compound with a known, measurable, monitorable metabolic effect and no long-term approved-drug safety dataset — precisely the conditions under which a clinician who can order and interpret a panel is worth the most, and the internet the least.

📊 Evidence Rating

Claim: MK-677 (ibutamoren) improves body composition in healthy adults. Rating: ⚠️ Promising but preliminary (as of this writing, 2026) Why: Randomized human trials establish that MK-677 durably raises GH and IGF-1 and produces a measurable increase in fat-free mass relative to placebo — real human outcome data that most Part III compounds do not have — but the functional benefits claimed on top of it were measured and did not appear, a genuine insulin-resistance signal is documented, the lean-mass gain is not cleanly separable from fluid retention, and the compound is not approved anywhere. What would change it: Adequately powered trials showing that the body composition change translates into a functional or clinical outcome, with metabolic effects characterized over multi-year exposure, would move this toward ✅. Trials showing that the added mass is predominantly fluid, or that the metabolic cost outweighs the compositional gain in the populations using it, would move it to ❌.

Notice why that rating is a ⚠️ when CJC-1295 plus ipamorelin will not be. The difference is not that MK-677 is a better or safer molecule. The difference is that someone did the trial. Real human outcome data, including data that partly disappointed its sponsors, outweighs mechanism plus enthusiasm.

15.5 Tesamorelin: the one with an approval

Now the chapter's teaching case, and the reason it is impossible to dismiss this class wholesale.

Tesamorelin is a GHRH analog that holds a regulatory approval. Specifically, it is approved for the reduction of excess visceral abdominal fat in patients with HIV-associated lipodystrophy.

Read that indication again and notice how narrow it is. Not "fat loss." Not "body recomposition." Not "in adults." A specific fat compartment, in a specific complication, in a specific patient population. Every one of those qualifiers was earned by a trial, and every one of them limits what can honestly be claimed.

The clinical problem it was built for

HIV-associated lipodystrophy is a real and consequential condition. In people living with HIV — particularly those treated in earlier antiretroviral eras — a characteristic redistribution of body fat can occur: fat is lost from the face and limbs while visceral adipose tissue, the fat packed around the abdominal organs, accumulates. This is not cosmetic. Visceral fat is metabolically active and associated with cardiovascular and metabolic risk, and the condition carried real quality-of-life burden as well.

Investigators had reason to think the GH axis was involved: the pattern resembled aspects of GH deficiency, and GH itself reduces visceral fat. But giving growth hormone directly brought exactly the problems Chapter 14 described, and in this population the glucose consequences were particularly unwelcome. So the strategy was the one this chapter is about — stimulate the axis with a GHRH analog engineered for stability, and see whether the resulting endogenous GH release reduced visceral fat without the full cost of exogenous GH.

🔬 Read the Study

```text FIGURE 15.2 — "A secretagogue that reached the finish line" [Tier 1 — verified canonical]

THE STUDY The tesamorelin phase 3 program: randomized, double-blind, placebo-controlled trials in adults with HIV-associated lipodystrophy and excess visceral abdominal fat, conducted over roughly six months with an extension period, with visceral adipose tissue measured by CT imaging as the primary endpoint. Supported US approval in 2010.

THE QUESTION In this specific population, does a stabilized GHRH analog reduce visceral adipose tissue relative to placebo, by an amount large enough to matter, without unacceptable metabolic harm?

WHAT IT SHOWS Yes, on the endpoint it tested. Tesamorelin produced a reduction in visceral adipose tissue on the order of 15 percent relative to baseline, against little change or a small increase in the placebo arm. IGF-1 rose, consistent with the intended mechanism. The effect was reproducible across the program — this was not a single positive study.

WHAT IT DOESN'T It does not show benefit in people without HIV-associated lipodystrophy — none were enrolled. It does not show general weight loss; the effect was on a specific fat compartment. It does not show a cardiovascular outcome benefit; reduced visceral fat is itself a surrogate for the hard outcomes people care about, and the trials were not designed or sized to test those. It does not show benefit in strength, athletic performance, recovery, or aging. And the effect was not permanent: visceral fat tended to return after discontinuation, which tells you the drug was suppressing an ongoing process rather than curing it.

THE VERDICT A completed, replicated, regulator-reviewed demonstration that stimulating the GH axis with a GHRH analog produces a measurable clinical effect in a defined population. The mechanism is real. The approval is real. The narrowness is also real, and was not an accident.

THE LESSON This is the strongest evidence in the entire secretagogue class — and it is evidence for one claim, in one population, on one endpoint. When someone cites tesamorelin to support a general secretagogue claim, they are borrowing the credibility of a specific trial to underwrite something that trial did not test. ```

💊 In the Clinic — what a narrow indication actually means

Patients regularly encounter a version of this argument: tesamorelin is FDA-approved, so GHRH analogs are proven to work. Untangling it is one of the more useful five minutes a clinician can spend.

An approval is not a general endorsement of a molecule. It is a regulator's judgment that, for a stated indication, in a stated population, at a stated exposure, the demonstrated benefit exceeded the demonstrated risk in the trials submitted. Every clause is load-bearing. Change the population and the benefit side of that equation is unmeasured; change the endpoint and you are outside what was tested.

Tesamorelin's approved label described a daily subcutaneous injection in adults with HIV-associated lipodystrophy, and carried the metabolic cautions the mechanism predicts — glucose monitoring, attention to fluid retention and joint symptoms, and the standard concerns attending any elevation of the GH/IGF-1 axis, including in people with active malignancy. Those cautions attach to the approved use in the studied population. They do not become less relevant when the same mechanism is engaged outside it; they become less monitored.

One practical point clinicians will recognize: the effect required continued administration, since visceral fat returned when it stopped. A patient asking whether a secretagogue is a course of treatment or an indefinite commitment is asking a good question, and here the trial data answered it.

📊 Evidence Rating

Claim: Tesamorelin reduces excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Rating: ✅ Strong clinical evidence (as of this writing, 2026) Why: Multiple randomized, placebo-controlled trials with an imaging-based primary endpoint showed a consistent, clinically meaningful reduction in visceral adipose tissue, reviewed and approved by a major regulator for exactly this indication in exactly this population. What would change it: Post-approval evidence that the visceral fat reduction fails to translate into meaningful health benefit, or that long-term metabolic or oncologic harms outweigh it in this population, would move this toward ⚠️. Nothing about this rating transfers to any other population or endpoint; those require their own trials and would receive their own ratings.

The double lesson

Tesamorelin does two jobs in this chapter, and they point in opposite directions. Both are true.

Its existence proves the mechanism is real. The secretagogue strategy demonstrably worked, once, for something. A GHRH analog raised endogenous GH, that GH did something measurable to a tissue, and a regulator agreed the effect was real and worth the risk. Any account of this class that treats it as pure fantasy is contradicted by an approved drug.

Its narrowness proves that a real mechanism does not license broad claims. The same program that established the mechanism established its boundaries. Tesamorelin's sponsors did not stop at HIV lipodystrophy out of modesty; they stopped there because that is where they ran trials and where the benefit-risk case closed. When a compound with a working mechanism, a funded program, and a successful approval does not expand to general fat loss or body recomposition, that absence is informative. The most capable version of this strategy, in the hands of people with every incentive and resource to extend it, holds one narrow indication.

Chapter 2 §2.9 put a number on the general version: roughly nine in ten compounds entering human trials never reach approval. Tesamorelin is the one in ten — and a demonstration that being the one in ten buys a specific claim and nothing more.

15.6 Pulsatile versus tonic: take the argument seriously first

Now the chapter's central mechanistic argument, and it deserves to be stated at its strongest before it is tested. Presenting a weak version of an opponent's case and then defeating it teaches nothing.

The case for stimulating rather than replacing

Here is the argument, made properly.

Growth hormone is not secreted continuously. It is released in discrete bursts, predominantly at night, with near-undetectable troughs between them, and there is good reason to think the pattern itself is part of the signal. Target tissues respond differently to pulsatile and continuous exposure to the same hormone, and receptor systems generally handle intermittent stimulation better than constant stimulation, because the trough gives receptors time to reset.

When you inject growth hormone, you overwrite that pattern. You produce a sustained elevation, the hypothalamic-pituitary axis detects it and suppresses its own output, and for as long as you continue, the gland is not doing its job. This is the standard argument against exogenous hormone replacement of any kind, and in outline it is correct.

A secretagogue, the argument goes, does something categorically different. It does not supply hormone; it asks the pituitary for hormone. Which means:

Pulsatility is preserved. The pituitary still releases in bursts, because that is how the pituitary releases. A stimulus raises pulse amplitude rather than replacing pulses with a plateau. You are amplifying a rhythm, not overwriting it.

The gland stays in use. No disuse, no suppression of the endogenous machinery, no shutdown to recover from.

Regulation is retained. The body's own control systems — somatostatin, IGF-1 feedback, the hypothalamic sensing that governs when a pulse is appropriate — remain in the circuit. If the axis does not want more hormone, it can decline. A secretagogue is a request; an injection is a fact.

There is a ceiling. Because the pituitary can only release what it has, a secretagogue cannot in principle produce the extreme, sustained elevations achievable by injecting hormone directly. The system's own limits act as a safety margin.

This is real physiology, not marketing. Every one of those points describes something true about how endocrine systems behave. They are why serious pharmacologists pursued secretagogues at all, and why tesamorelin exists. A reader who dismisses the argument as a sales pitch has misread the field.

Now let us test it.

Counter-argument one: the feedback loop is not on your side

The argument's most attractive phrase is "preserves the feedback loop." Ask what the feedback loop does.

Chapter 3 §3.4 established the shape of it, and §15.1 restated it: elevated IGF-1 inhibits GH release and raises somatostatin. So the sequence is:

You stimulate the pituitary. It releases more GH. The liver makes more IGF-1. The elevated IGF-1 signals the hypothalamus and pituitary to release less GH and to raise the brake.

The loop opposes you. That is what a negative feedback loop is for. It is not a courtesy the axis extends to you; it is a homeostatic mechanism whose entire purpose is to return the system to its set point and to resist exactly the change you are trying to produce.

Two consequences follow, and neither is comfortable for the original argument.

First, "preserving the feedback loop" is not a safety feature by itself. It is often stated as though the loop were a guardrail against excess, and to a degree it does constrain magnitude — that is the "ceiling" point, and it has some force. But a loop that resists your input is also a loop that erodes your effect. The mechanism limiting the extreme is limiting the intended result too.

Second, it predicts diminishing returns over continued use. A system under sustained pressure to release more of something, receiving a feedback signal telling it to release less, trends toward a new equilibrium closer to where it started than the initial response suggested. Add downregulation — receptors under persistent stimulation often become less responsive — and you have two independent reasons to expect a secretagogue's effect to attenuate. Whether and how fast that happens for any specific compound here is, for most of them, unmeasured.

Counter-argument two: extended duration is a different signal, not a more natural one

This is the sharpest point in the chapter, so read it slowly.

The pulsatility argument says secretagogues are superior because they preserve the body's natural rhythm. Now consider what an extended-duration analog does. CJC-1295 with DAC is engineered to deliver a sustained signal — days, not minutes — to an axis designed to receive pulses.

That is not preserving pulsatility. It is the opposite of preserving pulsatility. A GHRH-receptor stimulus present continuously for days is precisely the "flat, sustained, whole-body exposure that no physiological system ever produces" that Chapter 1 warned about and that the pulsatility argument was originally raised against.

The rhetorical move worth catching is this: the argument for secretagogues over injected GH rests on pulsatility, and then the most popular secretagogue design deliberately abandons pulsatility. You cannot have the benefit of both. Either the pattern matters — in which case a continuously present GHRH-receptor agonist is a problem needing justification — or the pattern does not matter, in which case the central argument for the whole class collapses.

To be fair to the design: the pituitary's own release machinery may still impose burstiness on the output even under a continuous input, so "sustained GHRH signal" does not necessarily mean "flat GH curve." That is a legitimate defense — and an empirical claim needing demonstration per compound rather than assumption. The shorter-acting analogs (sermorelin, modified GRF(1-29) without DAC, tesamorelin as a daily injection of a stable but not albumin-tethered molecule) are more plausibly delivering something pulse-like. That is one of the few places in this chapter where which specific molecule changes the analysis substantially.

And there is a precedent that should make anyone pause here.

🧬 The Molecule — the GnRH lesson, and why it is not a rhetorical flourish

Chapter 3 §3.5 introduced the cleanest demonstration in endocrinology that pattern is signal.

GnRH — gonadotropin-releasing hormone — is released by the hypothalamus in pulses, and those pulses drive the pituitary to release the hormones that run the reproductive axis. Deliver GnRH in pulses, and you stimulate the axis; this is used therapeutically to induce fertility in certain conditions.

Deliver the same molecule continuously, and after an initial surge the axis shuts down. The receptors desensitize, the pituitary stops responding, and downstream sex hormone production falls to near-castrate levels.

This is not a curiosity. It is the therapeutic basis of an entire approved drug class. Continuous GnRH receptor agonists — the -relin compounds Chapter 1 §1.8 flagged, leuprorelin and its relatives — are used to suppress testosterone in prostate cancer. A drug used to suppress an axis is a stimulant of that axis given continuously. Same receptor, same agonist, opposite outcome; the variable is the temporal pattern.

Now hold that next to an extended-duration GHRH analog. The GH axis is not the reproductive axis and the receptors differ, and it would be wrong to claim the same reversal has been demonstrated here — it has not, and asserting it would be exactly the mechanism-based overreach this book objects to when it runs in the other direction.

But the GnRH case establishes something modest and genuinely load-bearing: continuous stimulation of a pulsatile axis can produce the opposite of the intended effect, and this is not speculation because it is the mechanism of an approved cancer therapy. That is enough to make "sustained stimulation is at least as good as pulses" a claim requiring evidence rather than an assumption deserving the benefit of the doubt. Case Study 2 works through the comparison in full.

Counter-argument three: none of it establishes an outcome

The third counter-argument is the shortest and the most decisive.

Suppose every part of the pulsatility case is correct. Suppose secretagogues really do preserve rhythm, avoid suppression, retain regulation, and impose a natural ceiling. Suppose all four.

You still have not established that anything good happens to the person taking them.

Every one of those claims is about the shape of a hormonal signal. Not one is about strength, recovery, injury healing, body composition that matters, sleep, or health. The entire pulsatility argument, taken at maximum strength and granted in full, establishes that secretagogues are a more physiologically graceful way of raising growth hormone than injecting growth hormone.

Which brings us to the question the whole chapter has been circling.

15.7 What "raises growth hormone" proves, and what it does not

This is the most transferable section in this book. If you retain one thing from Part III, make it this.

"It raises growth hormone" is a mechanism claim. "It will improve your body composition and recovery" is an outcome claim. They are different kinds of statement, and a considerable amount of biology sits between them.

The compounds in this chapter genuinely do the first thing, and that should be conceded immediately and without hedging, because conceding it is what makes the rest of the argument credible. CJC-1295 raises GH and IGF-1. Ipamorelin raises GH. MK-677 raises both durably, as measured in randomized trials. Tesamorelin raises IGF-1 and reduces visceral fat. The mechanism is not in dispute. The surrogate moves.

Chapter 5 §5.6 defined the term you need. A surrogate endpoint is something measurable that stands in for the outcome you actually care about, on the theory that changing the surrogate changes the outcome. Cholesterol is a surrogate for cardiovascular events; bone density is a surrogate for fractures. GH and IGF-1 are surrogates for strength, function, body composition that matters, and health. And Chapter 5's central warning applies with full force: the arrow from surrogate to outcome is a hypothesis, not an assumption. Sometimes it holds. Sometimes the surrogate moves beautifully and the outcome does not follow, and sometimes the outcome moves in the wrong direction while the surrogate looks fine. Medicine has learned this repeatedly and expensively.

The seven steps, instantiated

Chapter 2 laid out the general sequence from a molecule binding a receptor to a person being better off. Here it is written specifically for this class, so you can see exactly where the evidence stops.

FROM COMPOUND TO OUTCOME — where the evidence ends for GH secretagogues

  STEP 1  The compound reaches the pituitary and binds its receptor
          (GHRH receptor, or GHS-R)                          ─── ESTABLISHED
  STEP 2  Binding causes growth hormone release               ─── ESTABLISHED
  STEP 3  GH release produces a sustained rise in IGF-1       ─── ESTABLISHED
          ────────────────────────────────────────────────────────────────────
          ↑ everything above this line is SURROGATE. All of it is real.
          ↓ everything below this line is OUTCOME. This is where it thins out.
          ────────────────────────────────────────────────────────────────────
  STEP 4  Elevated IGF-1 produces the intended tissue-level
          change — protein synthesis in muscle, lipolysis in
          the fat depot you meant — rather than an unintended
          one, or fluid retention that resembles one          ─── PARTLY, COMPOUND-SPECIFIC
  STEP 5  That tissue change produces a body-composition
          change large enough to measure reliably             ─── SHOWN for MK-677 and
                                                                   tesamorelin; ASSUMED elsewhere
  STEP 6  That composition change produces a functional
          outcome a person would notice — strength, recovery,
          capability, mobility                                ─── NOT SHOWN for any
                                                                   compound in this chapter
  STEP 7  The benefit survives subtraction of the harms and
          persists over years                                 ─── NOT STUDIED for any
                                                                   compound in this chapter
                                                                   outside its approved use

Every claim you will hear about this class in the wild is a Step 6 claim. Almost every piece of evidence offered in support is a Step 3 measurement. The gap between them is not a technicality that further mechanism can close. It is four biological steps, three of which have been tested for at least one compound and found not to close automatically.

Look again at Figure 15.1. That is the shape of the problem in a single trial: Steps 1 through 5 succeeded over two years in real people, and Step 6 did not follow. The surrogate did everything it was asked. The outcome did not arrive.

Why the gap is wider than it looks

Four reasons the arrow from Step 3 to Step 6 fails more often than intuition suggests.

The tissue may not be listening. Raising a hormone raises the signal; it does not guarantee the target responds. Receptor density, post-receptor signaling, and binding proteins all sit between a circulating concentration and a cellular effect. IGF-1 in particular circulates bound to a family of binding proteins, so total IGF-1 in a tube and IGF-1 available to a muscle cell are not the same quantity.

Lean mass is not muscle. GH axis stimulation causes sodium and water retention, and body composition scans register retained fluid as fat-free mass. A kilogram of "lean mass" is compatible with contractile tissue, water, or a mixture — and the harder the compound stimulates the axis, the more of the second you should expect. This is a standard caveat in the GH literature, and it is why functional endpoints exist.

Adaptation. §15.6 gave two independent reasons — feedback and downregulation — to expect the response to attenuate. A trial reporting week-4 IGF-1 does not tell you about month 12.

The outcome may be limited by something else entirely. If recovery from training is limited by sleep, protein intake, training load, or an unaddressed injury, raising GH does not remove the limiting factor. Adding more of a non-limiting input produces nothing, and this is the most common reason a mechanistically sound intervention does nothing measurable in practice.

🔍 Check Your Understanding

1. Someone shows you a lab report: IGF-1 up substantially after eight weeks on a secretagogue. Which step in the diagram does that document, and which step is their claim about?
2. Give two distinct explanations for a one-kilogram increase in "lean mass" on a body composition scan after GH axis stimulation, only one of which involves more muscle.
3. Chapter 2 §2.9 says roughly nine in ten compounds entering human trials never reach approval. Using the seven-step diagram, explain where most of those failures occur and why mechanism-level confidence does not predict them.

15.8 The outcome-evidence gap, compound by compound

Here is the state of play. The point of going compound by compound is that the answers are genuinely different, and a blanket verdict would be less accurate than the specifics.

Three observations about that table.

The first column is nearly all "yes." This class delivers on its mechanism. That is unusual for Part III and it should be stated plainly rather than buried.

The second column is where the class separates. Two compounds have human outcome trials; the rest do not. And the two that do are the two that went through formal development — which is the point Chapter 1 §1.8 was making about names. A laboratory code decades after discovery tells you development did not complete, and what formal development produces is trials with outcome endpoints. That is strong evidence about regulatory history and no evidence about pharmacology. CJC-1295 may be a perfectly good molecule. Nobody finished finding out.

The compounds most used are the compounds least studied. CJC-1295 and ipamorelin are almost certainly the most widely used compounds in this chapter and have the thinnest outcome evidence in it. That inversion is not an accident of science; it is a consequence of accessibility. Compounds that are easy to obtain are easy to obtain partly because nobody is running the trials that would create a regulated supply.

📊 Evidence Rating

Claim: CJC-1295 combined with ipamorelin improves body composition, recovery, or function in healthy adults. Rating: ⚠️→❌ — the surrogate claim is supported (⚠️ at minimum, arguably established); the outcome claim is ❌ (as of this writing, 2026) Why: Both compounds demonstrably raise growth hormone, and CJC-1295 has published early-phase human data showing sustained GH and IGF-1 elevation — that part is real and should not be denied — but there are no completed randomized human trials measuring body composition, recovery, or function as endpoints for either compound alone or in combination, and neither has a generic name or a completed development program behind it. What would change it: A randomized, placebo-controlled trial in healthy adults with a pre-registered functional or body-composition endpoint, adequately powered and independently conducted, would move the outcome claim in whichever direction the data pointed. Note that a trial showing further increases in GH or IGF-1 would change nothing, because that claim is already conceded.

That split is not fence-sitting; it is the rating system working correctly. Rule 6 says one molecule can carry many ratings, and rule 1 says a rating attaches to a claim with a population and an endpoint. "CJC-1295 raises IGF-1 in healthy adults" and "CJC-1295 improves recovery in healthy adults" are two claims with two evidence bases, and collapsing them into a single verdict on the molecule destroys the information you need.

It is also the honest thing to do. A reader who has used this combination and watched their IGF-1 panel move is not imagining it, and a book that told them they were would deserve to be disbelieved about everything else. The disagreement is not about whether the compound does something. It is about whether what it does is the thing they were sold.

15.9 Four ratings, four different reasons

Here is the chapter's rating set. Read the four together, because the interesting thing about them is not any individual verdict — it is that four compounds acting on the same axis, all of which demonstrably raise growth hormone, land in three different tiers for four different reasons.

📊 Evidence Rating

Claim: Sermorelin, GHRP-2, or GHRP-6 delivers the popular claims made for them — improved body composition, recovery, sleep, or anti-aging benefit in healthy adults. Rating: ❌ Hype outpaces evidence (as of this writing, 2026) Why: All three reliably stimulate growth hormone release, and none has completed randomized human trials measuring any of these outcomes; sermorelin's former approvals and GHRP-2's diagnostic use are real but concern entirely different claims, and using them as support is borrowing credibility across an indication boundary. What would change it: Randomized, placebo-controlled human trials with the relevant functional endpoints. Note that these compounds have existed for decades, which means the absence of such trials is not simply a matter of time — it reflects that no one with resources has considered the outcome question worth settling.

The four, side by side

Now check those four against the six rules from Chapter 5.

Rule 1 — a rating attaches to a claim with a population and an endpoint, never a molecule. Every row names both. "Tesamorelin: ✅" would be false as written; tesamorelin for athletic recovery has no rating in this book, because no one has tested it.

Rule 2 — ❌ describes the evidence, not the molecule. The ❌ on sermorelin does not say sermorelin does nothing; sermorelin measurably raises growth hormone. It says the confident version of the popular claim is unsupported by human outcome data.

Rule 3 — never upgrade with mechanism. This is the rule the chapter exists to enforce. Every compound here has a good mechanism, several elegant ones, doing exactly what they were designed to do. Not one of those facts moved a rating. Rule 4 — never downgrade with distaste. MK-677 is sold in the least regulated corner of this market, is not a peptide, and is frequently marketed with claims its own trial data contradicts. It still gets ⚠️, because a two-year randomized controlled trial outweighs the company it keeps.

Rules 5 and 6 — date-stamped and falsifiable; one molecule, many ratings. Each rating carries "as of this writing (2026)" and a condition that would change it; if you are reading this later, those conditions are the part to check. CJC-1295 carries two ratings in a single row, as does tesamorelin across the book — ✅ for its indication, unrated for everything else.

📋 Your Evidence Dossier

Field 3 — Mechanism, extended to indirect mechanisms.

Field 3 asks how a compound is supposed to produce its claimed effect. Until now, the compounds you have entered acted more or less directly: the molecule reaches a target tissue, binds a receptor there, and the effect follows. Semaglutide meets GLP-1 receptors and the effects follow from that meeting.

This chapter breaks that pattern, and Field 3 has to grow to accommodate it.

A growth hormone secretagogue does not act on the tissue you care about. It acts on a gland. The gland releases a hormone. The hormone acts on the liver. The liver releases a second messenger. That messenger acts on the tissue. The effect you want is at least two steps downstream of anything the compound touches — and every step is a place where the chain can weaken, be opposed by feedback, or be limited by something unrelated.

So when the mechanism is indirect, Field 3 needs to record the whole chain and mark where the evidence stops.

FIELD 3 — MECHANISM (indirect form)
  Direct target          the receptor the compound actually binds, and on what tissue
  Immediate effect       what happens at that tissue — measurable?
  Intermediate step(s)   what the immediate effect causes next
  Claimed final effect   the outcome the compound is sold for
  Steps between          count them
  Opposing forces        what in the body resists this chain
  Evidence stops at      the last step with human data behind it

Worked demonstration — CJC-1295 + ipamorelin

FIELD 3 — CJC-1295 + IPAMORELIN                      [worked demonstration]

  Direct target        CJC-1295: GHRH receptor, anterior pituitary
                       Ipamorelin: ghrelin receptor (GHS-R), anterior pituitary
                       NOTE: neither compound touches muscle, tendon, or fat directly.
                       Nothing in this entry is a claim about those tissues yet.

  Immediate effect     Increased pituitary growth hormone release. Measurable, but
                       awkwardly — GH is pulsatile, so a single draw is nearly
                       uninterpretable (§15.1). IGF-1 is the practical readout.

  Intermediate step 1  GH acts on the liver → increased IGF-1 production.
                       Measurable and reliably reported.
  Intermediate step 2  Elevated IGF-1 (and GH directly) act on muscle, adipose, and
                       connective tissue → altered protein synthesis and lipolysis.
                       Inferred from GH physiology; not measured for these compounds.
  Intermediate step 3  Those tissue changes accumulate into a body-composition change
                       large enough to detect. Not measured for these compounds.

  Claimed final effect Improved body composition, faster recovery, better sleep,
                       improved function in healthy adults.

  Steps between        FOUR, minimum, between receptor binding and the claimed outcome.

  Opposing forces      • IGF-1 negative feedback inhibits GH release and raises
                         somatostatin — the axis actively resists the change (§15.6)
                       • Possible receptor downregulation under sustained stimulation
                       • CJC-1295 with DAC delivers a SUSTAINED signal to a PULSATILE
                         axis — a different input, not a stronger natural one
                       • Fluid retention can register as lean mass, inflating any
                         apparent composition benefit

  Evidence stops at    INTERMEDIATE STEP 1. Human data supports GH and IGF-1 elevation.
                       Everything after that is mechanism, inference, and anecdote.

Now do this for your own entries

For each peptide in your dossier, answer one question first: does this compound act on the tissue where I want the effect, or on something upstream of it? If the answer is "upstream," use the indirect form above, count the steps, then find the last step with human data behind it and write it down. That single line — evidence stops at — is the most useful thing in the entire dossier, because it is the line marketing is designed to make you lose track of.

A note on scoring, since people ask. More steps is not automatically worse. Plenty of excellent drugs work indirectly, and tesamorelin — same axis, same number of steps — carries this chapter's strongest rating. What matters is not the number of steps but where the evidence stops relative to them. Tesamorelin's runs all the way to a measured tissue outcome in a defined population. CJC-1295's stops at a blood test.

Finally, revisit your Step 3 confidence note from Chapter 1 for any secretagogue in your set. The useful question is not whether you were wrong. It is whether you were more generous toward the compound you were already using.

Conclusion

Growth hormone secretagogues are the most interesting failure of inference in this book, and calling them that is not the same as calling them useless.

The strategy is sound in outline. Rather than supplying a hormone and suppressing the gland that makes it, ask the gland. The compounds built to do this work at the level they were designed to work at: GHRH analogs engage the GHRH receptor, ghrelin mimetics engage GHS-R, both raise growth hormone, and IGF-1 rises downstream. This chapter has not disputed any of that.

Tesamorelin proves the strategy can reach a clinical outcome. A stabilized GHRH analog reduced visceral adipose tissue in adults with HIV-associated lipodystrophy, across replicated randomized trials with an objective imaging endpoint, and a regulator agreed. Anyone who tells you secretagogues are pure fiction has to explain an approved drug. And tesamorelin's narrowness is the other half of the lesson. One indication, one population, one fat compartment — that is what a working mechanism, a funded program, and a successful approval bought.

The reason for the gap is §15.7, and it is the sentence to carry out of this chapter: "it raises growth hormone" is a measurement, "it will make you stronger" is a promise, and between them sit four biological steps that have been tested exactly twice in this entire class. When they were tested — two years, randomized, placebo-controlled, in real people — the surrogate performed flawlessly and the functional outcome did not follow.

If you use these compounds, the practical upshot is not a verdict but a shorter list of things worth knowing: which molecule you actually have, given that one popular name covers two different drugs; whether glucose and insulin sensitivity have been looked at in you specifically, since MK-677's signal there is documented and invisible without a blood test; whether what you are measuring is the outcome you want or a proxy for it; and what your own axis is doing over months rather than weeks. Every item on that list is something a clinician can help with and a forum structurally cannot, and none of it requires anyone to agree about whether the compounds work.

Chapter 16 turns to the compounds sold for healing rather than growth, where the evidence problem has a different shape: not a surrogate that moves without an outcome, but an animal literature so large and so consistent that it has been mistaken for a human one.

Key Terms

Growth hormone secretagogue — any compound that stimulates the pituitary to release growth hormone rather than supplying it. Includes GHRH analogs, ghrelin receptor agonists, and non-peptide molecules such as MK-677.

GHRH (growth hormone-releasing hormone) — the hypothalamic hormone that stimulates pituitary GH release; the accelerator of the axis. Native human GHRH is 44 amino acids, with activity in the first 29.

GHRH receptor — the pituitary receptor for GHRH; target of sermorelin, CJC-1295, and tesamorelin.

Somatostatin — the hypothalamic hormone that inhibits pituitary GH release; the brake. GH output at any moment is the net of GHRH and somatostatin.

IGF-1 (insulin-like growth factor 1) — the messenger produced mainly by the liver in response to growth hormone, through which most GH effects are mediated. Because it does not pulse, it is the stable readout of GH exposure — and also the negative feedback signal inhibiting further GH release.

Pulsatile secretion — release in discrete bursts rather than continuously. GH is strongly pulsatile, mostly nocturnal, and near-undetectable between bursts, which is why a single random GH measurement is nearly uninterpretable.

Tonic (continuous) stimulation — sustained, non-pulsatile receptor stimulation. For some axes it produces a categorically different result from pulsatile stimulation, up to and including suppression.

Ghrelin — the stomach-derived hormone known for stimulating appetite, which also potently stimulates GH release.

Ghrelin receptor (GHS-R) — the growth hormone secretagogue receptor; target of GHRP-2, GHRP-6, ipamorelin, and MK-677. Named before its natural ligand was identified.

GHRP (growth hormone releasing peptide) — the family of peptides acting at the ghrelin receptor; GHRP-6 and GHRP-2 are the prototypes.

Selectivity — the degree to which a compound engages its intended receptor and not others. Ipamorelin was designed for selectivity at GHS-R, with less of the appetite, cortisol, and prolactin activity associated with GHRP-6. A statement about receptors, not about safety.

DAC (Drug Affinity Complex) — a chemical group designed to bind covalently to circulating albumin, extending a peptide's duration from minutes to days. CJC-1295 with DAC carries it; the without-DAC version does not, and the two are different molecules sold under one name.

Sermorelin — GHRH(1-29), the unmodified active fragment of GHRH. Formerly marketed for diagnostic and pediatric uses and withdrawn for commercial reasons; now sold for claims it was never tested against.

Tesamorelin — a stabilized GHRH analog, and the only compound in this chapter with a regulatory approval: reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.

Ipamorelin — a pentapeptide ghrelin receptor agonist designed for selective GH release. No completed outcome trials for the claims it is sold for.

MK-677 (ibutamoren) — an orally active, long-acting ghrelin receptor agonist that is not a peptide. Raises GH and IGF-1 reliably; documented signal for increased blood glucose and reduced insulin sensitivity. Not approved.

Visceral adipose tissue — fat stored around the abdominal organs, distinct from subcutaneous fat and more strongly associated with metabolic risk. Tesamorelin's approved endpoint.

HIV-associated lipodystrophy — a redistribution of body fat seen in people living with HIV, with peripheral fat loss and visceral fat accumulation. The population in which tesamorelin was approved.

Negative feedback — an arrangement in which a system's output inhibits its own production. In the GH axis, IGF-1 inhibits GH release and raises somatostatin, so any successful elevation of GH generates the signal that opposes it.

Downregulation — reduced receptor number or responsiveness following persistent stimulation. One of two reasons to expect a secretagogue's effect to attenuate over continued use.

Tachyphylaxis — a rapidly diminishing response to repeated administration of the same stimulus.

Surrogate endpoint — a measurable stand-in for the outcome actually of interest, used on the hypothesis that changing it changes the outcome. GH and IGF-1 are surrogates for strength, function, body composition that matters, and health. The arrow from surrogate to outcome is a hypothesis, not an assumption.

Spaced Review

1. (Ch 3 + Ch 15) Chapter 3 §3.5 described GnRH: pulsatile delivery stimulates the reproductive axis, continuous delivery suppresses it, and the second is the basis of an approved cancer drug class. Explain what this does and does not establish about an extended-duration GHRH analog. Be precise about the limits of the analogy — a reader who concludes "therefore CJC-1295 with DAC suppresses the GH axis" has made the same category of error this book objects to elsewhere.

2. (Ch 14 + Ch 15) Chapter 14 rated growth hormone ✅ for approved deficiency and ❌ for anti-aging in healthy adults. This chapter rates tesamorelin ✅ for one indication and sermorelin ❌ for the popular claims. What single principle generates all four ratings, and why does it mean "GH-axis compounds work" and "GH-axis compounds don't work" are both wrong as stated?

3. (Ch 5 + Ch 15) A clinic advertises that its program "restores your growth hormone to youthful levels, verified by lab testing." Using Chapter 5's surrogate/outcome distinction and the seven-step diagram in §15.7, write the two-sentence response that concedes what is true and identifies exactly what is missing.

4. (Ch 1 + Ch 15) CJC-1295, GHRP-6, and MK-677 are laboratory codes; sermorelin and tesamorelin have generic names. State precisely what that difference is strong evidence about and what it is no evidence about at all. Then explain why GHRP-2 having an assigned generic name does not upgrade the evidence for the claims it is sold for.

5. (Ch 15, integrative) A person has used a CJC-1295 and ipamorelin combination for four months, their IGF-1 is measurably higher than at baseline, and they feel their recovery from training has improved. Identify the parts of that account you have no reason to doubt, the part that is a surrogate measurement, the part that is an outcome claim, and two confounders from §15.7 that could produce the reported experience without the compound producing the claimed effect. Then say what you would want measured — not to prove them wrong, but to make the next four months more informative than the last four.